Bradley J. Carver
Amministratore Delegato presso SynDevRx, Inc.
Posizioni attive di Bradley J. Carver
Società | Posizione | Inizio | Fine |
---|---|---|---|
SynDevRx, Inc.
SynDevRx, Inc. Miscellaneous Commercial ServicesCommercial Services SynDevRx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA. | Amministratore Delegato | - | - |
Presidente | - | - | |
Fondatore | - | - | |
Presidente | - | - |
Storia della carriera di Bradley J. Carver
Precedenti posizioni note di Bradley J. Carver
Società | Posizione | Inizio | Fine |
---|---|---|---|
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Presidente | 01/03/1995 | 31/01/2006 |
Treasurer | 01/03/1995 | 31/01/2006 |
Formazione di Bradley J. Carver
Michigan State University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Posizioni
President | 2 |
Treasurer | 1 |
Undergraduate Degree | 1 |
Settori
Commercial Services | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
SynDevRx, Inc.
SynDevRx, Inc. Miscellaneous Commercial ServicesCommercial Services SynDevRx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA. | Commercial Services |
- Borsa valori
- Insiders
- Bradley J. Carver
- Esperienza